

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

*(Use as many sheets as necessary)*

Sheet 1 of 6

<i>Complete if Known</i>	
<i>Application Number</i>	10/660,131
<i>Filing Date</i>	September 11, 2003
<i>First Named Inventor</i>	David H. Munn et al.
<i>Art Unit</i>	1647
<i>Examiner Name</i>	Regina M. DeBerry
<i>Attorney Docket Number</i>	M0351-287806

**U.S. PATENT DOCUMENTS**

FOREIGN PATENT DOCUMENT

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>4</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

6

## Complete if Known

Application Number	10/660,131
Filing Date	September 11, 2003
First Named Inventor	David H. Munn et al.
Art Unit	1647
Examiner Name	Regina M. DeBerry
Attorney Docket Number	M0351-287806

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	6	BABAN et al., "A Minor Population of Splenic Dendritic Cells Expressing CD19 Mediates IDO-Dependent T Cell Suppression Via Type 1 IFN Signaling Following 87 Ligation," <i>International Immunology</i> , 2005, 17(7): 909-919	
	7	BJORCK et al., "Isolation and characterization of plasmacytoid dendritic cells from Flt3 ligand and granulocyte-macrophage colony-stimulating factor-treated mice" <i>Blood</i> , 2001, 98(13): 3520-3526.	
	8	BORRAS et al., "Identification of Both Myeloid CD11c and Lymphoid CD11c Dendritic Cell Subsets in Cord Blood," <i>British Journal of Haematology</i> , 2001, 113: 925-931.	
	9	CADY et al., "1-Methyl-DL-tryptophan, beta-(3benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and beta-3-benzylthiophenyl-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase," <i>Archives of Biochemistry and Biophysics</i> , 1991, 291(2): 326-333 (Abstract)	
	10.	CHAPMAN et al., "Pharmacologically active benzo[b]thiophene derivatives. VIII Benzo[b]thiophene analogs of tryptophan and alpha-methyltryptophan, and some of their 5-substituted derivatives," <i>Journal of the Chemical Society, Section C: Organic Chemistry</i> , 1969, No. 14: 1855-1858 (Abstract).	
	11	DAGHER et al., "Pilot Trial of Tumor-Specific Peptide Vaccination and Continuous Infusion Interleukin-2 in Patients with Recurrent Ewing Sarcoma and Alveolar Rhabdomyosarcoma: An Inter-Institute NIH Study," <i>Med. Pediatr. Oncol.</i> DOI: 10.1002/mpo.10146	
	12	European Patent Office, Supplementary Partial European Search Report, Application No. EP 02 80 7233, Date of Completion of the Search October 19, 2005, 5 pages.	
	13	FRIBERG et al., "Indoleamine 2,3-Dioxygenase Contributes to Tumor Cell Evasion of T Cell-Mediated Rejection," <i>Int. J. Cancer</i> , 2002, 101: 151-155.	
	14	FRIBERG et al., "Indoleamine 2,3-dioxygenase (IDO) protects established tumors from T cell mediated rejection," <i>Proc. Amer. Ass. Cancer Res. Ann. Meet.</i> , 2000, No. 714, page 112 (Abstract).	
	15	FRUMENTO et al., "Inhibition of T cell proliferation by the purified enzyme indoleamine 2,3-dioxygenase," <i>Human Immunology, The European Federation for Immunogenetics 14<sup>th</sup> Annual Conference, April 4-7, 2000</i> , 61: page S140 (Abstract)	
	16	GROHMANN et al., "IFN- $\gamma$ Inhibits Presentation of a Tumor-Self Peptide by CD8a <sup>+</sup> Dendritic Cells Via Potentiation of the CD8a <sup>+</sup> subset" <i>Journal of Immunology</i> , 2000, 165(3): 1357-1363.	
	17	HWU et al., "Indoleamine 2,3-Dioxygenase Production by Human Dendritic Cells Results in the Inhibition of T Cell Proliferation" <i>J. Immunol.</i> , 2000, 164: 3596-3599.	
	18	International Search Report for PCT/US02/11319, filed April 12, 2002 mailed September 6, 2002.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3 of 6

**Complete if Known**

Application Number	10/660,131
Filing Date	September 11, 2003
First Named Inventor	David H. Munn et al.
Art Unit	1647
Examiner Name	Regina M. DeBerry
Attorney Docket Number	M0351-287806

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	19	LEE et al., "Pattern of Recruitment of Immunoregulatory Antigen-Presenting Cells in Malignant Melanoma," <i>Laboratory Investigation</i> , 2003, <u>83</u> (10): 1457-1466.	
	20	MELLOR et al., "Extinguishing Maternal Immune Responses during Pregnancy: Implications for Immunosuppression," <i>Seminars in Immunology</i> , 2001, <u>13</u> (4): 213-218.	
	21	MELLOR et al., "Tryptophan catabolism and T cell tolerance: immunosuppression by starvation?" <i>Immunology Today</i> , 1999, <u>20</u> : 469-473.	
	22	MELLOR et al., "Tryptophan catabolism prevents maternal T cells from activating lethal anti-fetal immune responses," <i>J. Reprod. Immunol.</i> , 2001, <u>52</u> (1-2): 5-13.	
	23	MELLOR et al., "TLA-G transgenic mice," <i>J. Reprod. Immunol.</i> , 1999, <u>43</u> : 253-261.	
	24	MELLOR et al., "Immunology at the maternal-fetal interface," <i>Ann. Rev. Immunol.</i> , 2000, <u>18</u> : 367-391.	
	25	MELLOR et al., "IDO expression by dendritic cells: tolerance and tryptophan catabolism" <i>Nat. Immunol. Rev.</i> , 2004, <u>4</u> : 762-774.	
		<b>DUPLICATE</b>	
	26	MUNN et al., "Ligation of B7-1/B7-2 by Human CD4+ T Cells Triggers Indoleamine 2,3-Dioxygenase Activity in Dendritic Cells," <i>Journal of Immunology</i> , 2004, <u>173</u> : 4100-4110.	
	27	MUNN et al., "Dendritic Cells Have the Option to Express IDO-Mediated Suppression or Not," <i>Blood</i> , 2005, <u>105</u> (6): 2618.	
	28	MUNN et al., "Macrophage inhibition of T cell activation via depletion of tryptophan," <i>Blood</i> , 1998, <u>48</u> -IV, (Abstract).	
	29	MUNN et al., "Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase," <i>Science</i> , 2002, <u>297</u> : 1867-1870.	
	30	MUNN et al., "Regulation of T cell activation by macrophage (Mvariant phi)-mediated tryptophan (TRP) depletion," <i>FASEB Journal</i> , 1998, <u>12</u> : page A276 (Abstract).	
	31	MUNN et al., "Tolerogenic Antigen-Presenting Cells," <i>Ann. NY. Acad. Sci.</i> , 2002 <u>961</u> : 343-345.	
	32	OSUGI et al., "Myeloid Blood CD11c+ Dendritic Cells and Monocyte-Derived Dendritic Cells Differ in their Ability to Stimulate T Lymphocytes," <i>Blood</i> , 2002, <u>100</u> (8): 2858-2866.	
	33	PACANOWSKI et al., "Reduced blood CD123 <sup>+</sup> (lymphoid) and CD11c <sup>+</sup> (myeloid) dendritic cell numbers in primary HIV-1 infection" <i>Blood</i> , 2001, <u>98</u> (10): 3016-3021.	

Examiner Signature	Date Considered
--------------------	-----------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.  
Include copy of this form with next communication to applicant.

<sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.